SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-20-000089
Filing Date
2020-08-06
Accepted
2020-08-06 16:11:19
Documents
16
Period of Report
2020-08-06
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20200806.htm   iXBRL 8-K 47480
2 EX-99.1 rvncq220exhibit991.htm EX-99.1 243584
8 newrevancelogo1.jpg GRAPHIC 11936
  Complete submission text file 0001479290-20-000089.txt   462207

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20200806.xsd EX-101.SCH 2458
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20200806_cal.xml EX-101.CAL 744
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20200806_def.xml EX-101.DEF 1689
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20200806_lab.xml EX-101.LAB 24275
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20200806_pre.xml EX-101.PRE 12680
9 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20200806_htm.xml XML 10804
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 201081716
SIC: 2834 Pharmaceutical Preparations